Skip to content

The randomized duble blind parallel-group comparison test of the effect for eyestrain of the Bilberry extracts

The randomized duble blind parallel-group comparison test of the effect for eyestrain of the Bilberry extracts - The test of the effect for eyestrain of the Bilberry extracts

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000020866
Enrollment
120
Registered
2016-02-03
Start date
2016-02-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eyestrain

Interventions

Bilberry extract 240mg/day, 12weeks Placebo, 12weeks

Sponsors

HUMA R&D Co.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1, Aged=>20 years,Male and female 2, Japanese male and female 3, PC work or driving 5 hours or more a day 4, Visual acuity with the naked eyes is 0.1 or more

Exclusion criteria

Exclusion criteria: 1, Subjects who have previous medical history and/or current medical history of serious diseases (e.g., digestive organ, liver, pancreas, heart and/or kidney). 2, Subjects who take medicines. 3, Subjects who have an eye disease. 4, Subjects who have previous medical history of drug and/or food allergy. 5, Subjects who have previous medical history and/or current medical history of drug dependence and/or drug abuse. 6, Subjects who work time is irregular. 7, Subjects who have undergone LASIK. 8, Subjects who are using the reading glasses. 9, Subjects who constantly use supplements containing bilberry extract and/or functional foods or drug affecting eyestrain. 10, Subjects who have been enrolled in the other clinical trials within about last 1 month. 11, Subjects who is during pregnancy, lactation and/or wish to become pregnant in clinical test. 12, Subjects who have taken over 200 mL of blood within the last one month prior to the current study. 13, Subjects who have been determined ineligible by principal investigator or sub-investigator.

Design outcomes

Primary

MeasureTime frame
Near-reflex: intake 0,4,8,12 weeks

Secondary

MeasureTime frame
Subjective symptoms: intake 0, 2, 4, 6, 8, 10, 12 weeks Eyestrain questionnaires: intake 0, 4, 8, 12 weeks Safety(blood test, urinary test, history taking):intake 0, 12 weeks

Countries

Japan

Contacts

Public ContactMarie Kosehira

Omnica Co.,Ltd Research team

kosehira@omnica.co.jp03-5840-9811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026